Navigation
banner

Biomarker Summit

2018-04-192018-02-132017-11-27
Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Bruce W.M. Jordan

Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
 
About Speaker:

Bruce joined the Roche Pharmaceuticals Herceptin team in Basel in 2005, leading the global HER2 Testing/Companion Diagnostics (CDx) activities. Since January 2013 he is VP - International Business Leader – Personalised Healthcare Solutions at Roche Diagnostics – Centralised and Pont of Care Solutions at their HQ in Rotkreuz, Switzerland.

He has worked on CDx development & commercialization out of both the Pharmaceuticals and Diagnostics Divisions over the past 11 years at Roche, across therapeutic areas such as Neurology, Immunology, Fertility and Oncology.

Bruce trained in Laboratory Medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently gaining State Registration in Haematology and Transfusion Medicine at Southampton General Hospital. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany.

Bruce has also represented the diagnostics industry as a Corporate Representative at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and is a Fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K., and a member of the European Society of Pharmacogenomics and Personalised Therapy (ESPT)

Douglas Galasko

Douglas Galasko
Professor of Neurosciences
UCSD
Douglas Galasko
Professor of Neurosciences
UCSD
 
About Speaker:

Dr. Douglas Galasko obtained medical training in South Africa, Neurology training at John Hopkins Hospital and Fellowship training in dementia at UC San Diego. He has been a faculty member in the Dept of Neurosciences at UCSD since 1987, and currently holds the rank of Professor. He is Associate Director of the NIH-funded Alzheimer’s Disease Research Center at UCSD. His primary clinical and research focus is dementia and neurodegenerative disorders. Specific areas of interest include biomarkers to assist in diagnosis and understand disease mechanisms for Alzheimer’s and Parkinson’s disease, and translational research using novel therapeutic approaches. He is an author of over 300 journal articles and reviews related to dementia.

William (Frank) Peacock

William (Frank) Peacock
Professor, Emergency Medicine
Baylor College of Medicine
William (Frank) Peacock
Professor, Emergency Medicine
Baylor College of Medicine
 
About Speaker:

Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine, Associate Chair, and Research Director for the department of Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. He serves as a member of the Accreditation Management Board for the American College of Cardiology, as well as on the Get With The Guidelines Science Subcommittee of the American Heart Association.

With over 500 peer reviewed publications, predominantly on heart failure and acute coronary syndromes, Dr. Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of Heart Failure, Short Stay Management of Chest Pain, and Short Stay Management of Atrial Fibrillation.

Dr. Peacock is the 2004 and 2010 winner of the Best Research Paper Award from the American College of Emergency Physicians. He continues to serve as PI or co-PI for many high profile national and international clinical trials. His research focus is all aspects of cardiovascular emergency medicine. He is also the founder of Comprehensive Research Associates, LLC, a contract research organization and Emergencies in Medicine, LLC, a medical education company. Finally, Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital, Detroit, Michigan.

Nathan Price

Nathan Price
ISB Associate Director and Professor
Institute for Systems Biology
Nathan Price
ISB Associate Director and Professor
Institute for Systems Biology
 
About Speaker:

Dr. Price is Professor & Associate Director of the Institute for Systems Biology (ISB) in Seattle, WA. He is also Affiliate Faculty in the Departments of Bioengineering, Computer Science & Engineering, and Molecular & Cellular Biology at the University of Washington. He is Co-Founder and on the Board of Directors of Arivale. Nathan has won numerous awards for his scientific work, including a Howard Temin Pathway to Independence Award from the National Institutes of Health, a National Science Foundation CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, a Camille Dreyfus Teacher-Scholar award, the 2016 Grace A. Goldsmith Award, and was named as one of the inaugural “Tomorrow’s PIs” by Genome Technology. Dr. Price has published over 100 peer-reviewed scientific publications and serves on editorial boards for many leading scientific journals including Science Translational Medicine and Cell Systems. Dr. Price served on the National Academy of Medicine committee to review omics-based tests to predict clinical outcome in clinical trials. Dr. Price has also served on scientific advisory boards for a number of companies and institutes including Roche (personalized healthcare division), Habit, Trelys, Cleveland Clinic’s Center for Functional Medicine, the Novo Nordisk Foundation Center for Biosustainability, and the University of Washington’s Public Health Genomics Institute. He is also a fellow of the European Society of Preventive Medicine.

PLENARY SPEAKERS
TBA (from CGI)
TBA (To Be Announced)

CGI
 
About Speaker:
Gary Gustavsen

Gary Gustavsen
Vice President
Health Advances
Gary Gustavsen
Vice President
Health Advances
 
About Speaker:

Gary Gustavsen joined Health Advances in 2005 and leads its Personalized Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his Bachelors degree in Biomedical Engineering from Duke University and his Masters degree in Biomedical Engineering from Stony Brook University.

 

 

Thomas Kleen

Thomas Kleen
Vice President, Immune Monitoring and Specialty Lab Services
Precision For Medicine
Thomas Kleen
Vice President, Immune Monitoring and Specialty Lab Services
Precision For Medicine
 
About Speaker:

Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis.  Prior he held the position of Director, Business and Technology Development and the function of Director, Assay Development and R&D at CTL, USA He received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany.  During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections.  He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematologic al disorders and malignancies after treatment with full myelo-ablative regimens (http://www.linkedin.com/in/thomasokleen).

His expertise is in the areas of immunology, vaccine and biologic evaluation, immunogenicity and oncology.  One focus is monitoring of Cell Mediated Immunity (CMI) and Bio-markers during immunotherapy, vaccine development and detection of adverse immune reactions during drug development.  He spends significant time educating pharmaceutical entities and governmental agencies about validated, standardized, GLP compliant technologies, which can be deployed today during pre-clinical and clinical trials, for sample logistics and immune monitoring.
Since 2009 Dr. Kleen is member of the SITC-FDA Task Force on Immunotherapy Biomarkers, which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.

Parag Mallick

Parag Mallick
Associate Professor, Canary Center for Cancer Early Detect
Stanford University
Parag Mallick
Associate Professor, Canary Center for Cancer Early Detect
Stanford University
 
About Speaker:

Dr. Parag Mallick is an Associate Professor at Stanford University. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology and nanotechnology. Dr. Mallick received his undergraduate degree in Computer Science from Washington University in St. Louis. He then obtained his Ph.D. from UCLA in Chemistry & Biochemistry, where he worked with Dr. David Eisenberg. He completed Post-Doctoral studies at The Institute for Systems Biology, in Seattle, WA with Dr. Ruedi Aebersold. Beyond studying fundamental disease mechanisms, his group has been pioneering novel approaches for enabling personalized and predictive medicine. This work has led to the creation of several successful companies. In addition, he is actively advising dozens of companies at various stages and working with venture funds on both scientific and fiscal evaluation of potential investments. Recently, he has been working to develop new funding vehicles to bring innovative, world changing advances to market.

John Schilling

John Schilling
Director & Advisor of Diagnostics
Eli Lilly
John Schilling
Director & Advisor of Diagnostics
Eli Lilly
 
About Speaker:

John Schilling, MBA, is a seventeen-year employee of Eli Lilly & Co., who currently is Director – Advisor of Diagnostics for the Personalized Medicine - Tailored Therapeutics Division within Lilly Research Laboratories.   John is responsible for executing the global diagnostic personalized medicine strategy to enable the capabilities to deliver for the global drug teams across Lilly’s pharmaceutical business units.  John’s prior responsibilities at Lilly have been as Global Marketing Director for the global Forteo and Evista brands.

Prior to Eli Lilly, John has worked as Marketing Director for Bausch & Lomb’s pharmaceutical division representing the anti-allergy and dry eye products.  He also was U.S. Brand Manager for AstraZeneca’s Prilosec brand.  Prior to John’s pharmaceutical experience, he worked in the diagnostic industry for Abbott Laboratories Diagnostics Division, Sanofi Diagnostics Pasteur, Bayer Diagnostics and Centocor in different sales, sales management, global marketing and business development roles. 

Cristina Stefan

Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
 
About Speaker:

Experienced, innovative oncologist with clinical and academic background, also with industry experience I had founded a number of institutes including the African Cancer Institute at Stellenbosch University in Cape Town, the African Medical Research and Innovation Institute, the African Pediatric and Adolescent Group and had the original initiatives such as the first successful twinning between 2 oncology units in Africa and the formation of the health economics group.

From head of an academic unit of pediatric hematology oncology to vice president of the Medical Research Council in South Africa and first woman president  of African Organization for Research and Training in Cancer (Aortic) I held a number of successful management and leadership positions. Strategic expertise across the entire oncology spectrum, from diagnostics to pharma, from innovation to effective management and leadership with in depth knowledge and experience of low and mid income countries, I have been working in more than 25 African countries. 

Author and coauthor of 3 oncology books, member of Academy of Science and Fellow of the Royal Society of Science in South Africa and Romania, I was voted in 2016 the most influential African woman in business and government.

Lorenzo Trippa

Lorenzo Trippa
Associate Professor, Biostatistics
Dana-Farber Cancer Institute, Harvard Medical School
Lorenzo Trippa
Associate Professor, Biostatistics
Dana-Farber Cancer Institute, Harvard Medical School
 
About Speaker:

Lorenzo Trippa, PhD, is an Associate Professor in the Department of Biostatistics and Computational Biology at Dana-Farber, and an Associate Professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. His research interests include clinical trials design; Bayesian nonparametrics; the development of prediction models in personalized medicine; computational methods for Bayesian adaptive designs; computational methods for Bayesian inference; and meta-analyses in personalized medicine. Trippa is a winner of the Savage PhD Thesis Award from the International Society for Bayesian Analysis. He holds a PhD in Statistics from Bocconi University, Milan, Italy, and an MS in Statistics (cum laude) from Milan's Bicocca University.

Oncology Biomarkers
DISTINGUISHED SPEAKERS
Jaffer Ajani

Jaffer Ajani
Professor of Medicine
University of Texas MD Anderson Cancer Center
Jaffer Ajani
Professor of Medicine
University of Texas MD Anderson Cancer Center
 
About Speaker:

Dr. Jaffer A. Ajani is a Professor of Cancer Medicine at the MD Anderson Cancer Center at The University of Texas in Houston, Texas.

Dr. Ajani earned his medical degree at Government Medical College in Nagpur, India and completed a residency program in general surgery and orthopedics at the Government Medical College.  After completing two more residency programs in family practice and internal medicine at Altoona General Hospital, Pennsylvania State University, Altoona, Pennsylvania, and Tulane University School of Medicine, New Orleans, Louisiana, respectively, Dr. Ajani was awarded a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

Certified in Medical Oncology by the American Board of Internal Medicine, Ajani has authored over 500 peer-reviewed articles and was cited in Good Housekeeping Magazine as being among the Best Doctors in America for GI Cancers.

Dr. Ajani is the Chair of 2 (gastric and esophageal cancers) guidelines of NCCN. He is also the lead for gastric cancer classification by AJCC8. He is the chief scientific officer of International Society of GI Oncology. He provides service to many large societies (such as ASCO, AACR, AGA, SSO, JSS, IGCC, JSMO, CSCO, and SLAGO).

 

Cedric Dos Santos

Cedric Dos Santos
Principal Scientist | Heme/Onc Clinical Biomarkers and Diagnostics
Amgen
Cedric Dos Santos
Principal Scientist | Heme/Onc Clinical Biomarkers and Diagnostics
Amgen
 
About Speaker:

Cedric received his Ph.D in Oncology from the University of Toulouse, France where he studied mechanisms underlying the PI3K/Akt and mTOR pathways activation in Acute Myeloid Leukemia. He did his post-doctoral training at City of Hope, Duarte, CA with Dr. Ravi Bhatia and Dr. Steve Forman assessing the impact of small molecules and immunotherapy (CAR-T) on AML stem/progenitor cells maintenance and drug resistance. After his training he joined the University of Pennsylvania and continued to work on AML and immunotherapy. Cedric joined Amgen and the Clinical Biomarkers and Diagnostics group in June 2015 where he rapidly became the Therapeutic Area lead for all Immuno-Oncology programs (BiTE® and CAR-T) at Amgen within the Leukemia and Lymphoma space including the first FDA approved BiTE® Blincyto®. Cedric recently took more responsibility and he is now responsible for the Heme/Onc pipeline and Clinical Biomarker strategy at Amgen.

Michael Heller

Michael Heller
Professor
University of California, San Diego
Michael Heller
Professor
University of California, San Diego
 
About Speaker:

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and he developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987.  He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989.  He was a co-found of Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller was a Professor (now adjunct professor) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has recently co-founded a new company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, DC and AC electrokinetic devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to a large number of scientific conferences, which now include recent meetings on cell free nucleic acid and exosome biomarkers for cancer detection and molecular diagnostics. He also has over 55 issued US patents in the molecular diagnostics, biotechnology and nanotechnology areas.

Louis Levy

Louis Levy
Director Corporate & Business Development
Ultivue
Louis Levy
Director Corporate & Business Development
Ultivue
 
About Speaker:

Louis Levy began his life science career with Cepton, a strategy consulting boutique for French mid-size biotechs.

As a Harvard Blavatnik Fellow, he worked on the commercialization of the Harvard technology conducive to the launch of Ultivue in 2015. Since then, he has spearheaded corporate and business development functions.

He is a graduate from the French grande école Telecom Bretagne, with a master’s degree in engineering and from Harvard Business School, with an MBA.

Sandip Patel

Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
 
About Speaker:

Sandip Patel, MD.  Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center

Dr. Sandip Patel, MD is a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials.  His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.

He is co-leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD.  He is Assistant Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs.  Dr. Patel earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center. He is triple board-certified in internal medicine, medical oncology, and hematology and was named a “Top Doc” in the most recent San Diego Magazine Physicians of Exceptional Excellence survey.

 

Tony Pircher

Tony Pircher
Director of Immunochemistry
Biocept
Tony Pircher
Director of Immunochemistry
Biocept
 
About Speaker:

Dr. Pircher joined the R&D department at Biocept Inc. in February 2001 and is currently leading the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of predictive and/or prognostic CTC assays. He has extensive experience in developing proteomic and genomic diagnostic assays and is the inventor on several Biocept patents.

He received his Ph.D. in molecular endocrinology from the Karolinska Institute, Stockholm, mentored by Dr. Lars-Arne Haldosen and the world renowned steroid receptor scientist Dr. Jan-Ake Gustafsson. During his postdoctoral training he worked in the field of molecular hematology at the Pennsylvania State University in the highly prolific research lab of Dr. Don M Wojchowski, where he gained extensive experience in the enrichment of erythroid progenitor cells from blood, bone marrow and spleen. He acquired expertise in protein alteration, expression, detection and purification technologies, antibody production and cellular reporter systems.

Elodie Sollier

Elodie Sollier
Chief Scientific Officer
Vortex Biosciences
Elodie Sollier
Chief Scientific Officer
Vortex Biosciences
 
About Speaker:

Elodie is Co-Founder, Chief Scientific Officer and Vice-President Research & Development for Vortex Biosciences, heading the initiatives for the commercialization of microfluidic devices for cancer research and diagnostics. Elodie received a Physics Engineering Degree from Grenoble Institute of Technology and a PhD in Physics for Life Science from CEA LETI Minatec at Grenoble, France. Her PhD was followed by post-doctoral research in Bioengineering Department, University of California, Los Angeles, with Professor Dino Di Carlo. Her work resulted in the publication of articles in peer-reviewed journals, review papers, presentations in international conferences, and several patents including technologies licensed to Vortex Biosciences from UCLA.

Elodie’s expertise includes the development of new microfluidic devices for biological applications, focusing especially on blood sample preparation and analysis. She has been investigating different microfabrication approaches for transitioning from laboratory research to commercialization.

Cardiovascular Biomarkers
DISTINGUISHED SPEAKERS
David Liem

David Liem
Clinical Study Coordinator
University of California Los Angeles
David Liem
Clinical Study Coordinator
University of California Los Angeles
 
About Speaker:

David Liem received his MD and a clinical fellowship training in cardio-thoracic surgery at the Academic Medical Center in Amsterdam in the Netherlands. Subsequently, he completed his PhD training in Experimental Cardiology at the Erasmus University in Rotterdam, the Netherlands. David Liem has had extensive experience in cardiovascular medicine and physiology. He currently serves as the Clinical Studies Coordinator at UCLA the NIH Heart BD2K Center of Excellence for Biomedical Computing at the UCLA School of Medicine. His main interest and focus are in translational medicine and Big Data science with patient care.

J. Brent Muhlestein

J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine
University of Utah
J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine
University of Utah
 
About Speaker:

Dr. Joseph Brent Muhlestein is Director of Cardiology Research at Intermountain Medical Center and Professor of Medicine at University of Utah in Salt Lake City, Utah. He received his BS degree in chemistry from Brigham Young University and his MD degree from the University of Utah.  He completed his residency in internal medicine and fellowships in cardiology and interventional cardiology at Duke University. In 1992, after a short stay as faculty at Duke University, he moved to Salt Lake City where he has divided his time between caring for heart patients, directing cardiovascular research and teaching medical students and residents.  Dr. Muhlestein’s research interests include new interventional technologies, cardiovascular clinical outcomes, and the evaluation of possible underlying causes of, and novel risk factors associated with, the development and progression of atherosclerosis, the major underlying cause of heart attacks.

John Nolan

John Nolan
President
Cellarcus Technologies
John Nolan
President
Cellarcus Technologies
 
About Speaker:

John Nolan is Professor at the Scintillon Institute, where his group develops new instrumentation, reagents, and assays for cytometry and single cell analysis. Recently, his group has developed quantitative and reproducible single vesicle analysis tools for the study of EVs. He earned BS degrees (Biology and Chemistry) at the University of Illinois, and a PhD (Biochemistry) from Penn State. He has served as Director of the National Flow Cytometry Resource at Los Alamos National Lab, President of the International Society for Advancement of Cytometry, and serves on the editorial boards of Cytometry and Current Protocols in Cytometry.

Jeffrey Price

Jeffrey Price
Chief Executive Officer
Vala Sciences
Jeffrey Price
Chief Executive Officer
Vala Sciences
 
About Speaker:

Jeff Price received his MD in 1985 from Loma Linda University and his PhD in bioengineering in 1990 from UCSD, where his lab created what became the IC 100 HCS instrument, first via Q3DM, which he founded in 1998, and then at Beckman Coulter, which purchased Q3DM in 2003. In 2004, he joined the Sanford-Burnham-Prebys Medical Discovery Institute (SBP) where he participated in creating the Prebys Center for Drug Discovery, one of four primary national screening centers funded by the NIH MLSCN/MLPCN program. In 2004, he also founded Vala Sciences, which in collaboration with SBP via NIH STTR funding, created and commercialized the Kinetic Image Cytometer. In 2015 he was appointed professor at The Scintillon Institute and Adjunct Professor at SBP.

Rhonda Rhyne

Rhonda Rhyne
Chief Executive Officer
Prevencio
Rhonda Rhyne
Chief Executive Officer
Prevencio
 
About Speaker:

Rhonda Rhyne has more than 25 years of executive medical technology research and commercialization experience and is currently CEO, Chief Translational Medicine Officer and Board Director for Prevencio, Inc., a Seattle-based company developing multi-protein blood tests for obstructive heart disease; 1-year risk for myocardial infarct, stroke, and CV death; obstructive peripheral artery disease…and more. She also serves as Board Director for Aminex Therapeutics and OtoNexus Medical Technologies, both Seattle-area companies. As a medical technology industry leader, Rhonda has received multiple awards, including Ernst & Young's Entrepreneur of the Year--Medical Products, San Diego; Deloitte's Fast 50 for 50 Fastest Growing Technology and Life Science Companies in Southern California; San Diego's Business Journal's Women Who Mean Business; and Athena's Pinnacle Individual in BioSciences. Rhonda also authored the women’s leadership book, Keys to the Corner Office: Success Strategies for Women by Women (www.keytothecorneroffice.com). A portion of net proceeds is donated to OUR Rescue, a nonprofit dedicated to fighting sex trafficking. Rhonda received her Bachelor of Pharmacy from Washington State University and MBA from University of California, Los Angeles (UCLA). @rhondarhyne, www.linkedin.com/in/rhondarhyne, www.prevenciomed.com

James Snider

James Snider
President
Critical Diagnostics
James Snider
President
Critical Diagnostics
 
About Speaker:

Dr. Snider received his Ph.D. in biochemistry from The University of South Carolina in 1990 and pursued postdoctoral studies in the biological response modifiers program at the NCI. Since then he has held several positions in various companies. In 2005 he became president of Critical Diagnostics and in that role has lead the company from formation to become a multinational corporation. He has published several papers in peer reviewed journals and has over a dozen patents.

Jim Turk

Jim Turk
Pathologist Director
Amgen
Jim Turk
Pathologist Director
Amgen
 
About Speaker:

Jim Turk completed BA in Biology at Washington University, St.Louis, Doctor of Veterinary Medicine (DVM) at the University of Missouri, Columbia, PhD at College of Veterinary Medicine, Washington State University Pathology residency the Washington Animal Diagnostic Laboratory in Pullman, WA.  

Jim is certified in anatomic pathology by the American College of Veterinary Pathologists.  

Jim has received numerous teaching awards as an Associate Professor in the Department of Veterinary Pathology, School of Veterinary Medicine Pathology, Louisiana State University, Baton Rouge, & Full Professor in the Departments of Veterinary Pathobiology and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia. 

Dr. Turk was Pathology Core leader for a Program Project Grant awarded by the National Heart Lung and Blood Institute using the pig as a model to study the impact of exercise on diet-induced atherosclerosis. Jim has worked at Merck, Westpoint PA, and Pfizer, St. Louis. 

Dr. Turk  is currently employed as a Pathologist Director in Comparative Biology and Safety Sciences at Amgen, Thousand Oaks, CA.

Szilard Voros

Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
 
About Speaker:

Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.

Inflammatory & Immunological Biomarkers
DISTINGUISHED SPEAKERS
Mark Curran

Mark Curran
Vice President, Immunology, Systems Pharmacology & Biomarkers
Janssen
Mark Curran
Vice President, Immunology, Systems Pharmacology & Biomarkers
Janssen
 
About Speaker:

Dr. Curran is currently Vice President of Immunology Systems Pharmacology and Biomarkers at Janssen Research & Development, LLC. His team is responsible for biomarker strategy, implementation, analysis and development and commercialization of companion diagnostics (Co-Dx) for immunology assets.

Mark’s experience in drug development includes seven years with Janssen and five years at Bristol Myers-Squibb. In addition to biomarker responsibilities he has lead clinical development and Phase 1 and 2 trials for multiple compounds in immunology. Prior to joining the pharmaceutical industry, Mark gained valuable experience in biotech and venture oriented companies with focus on genomics, diagnostics and drug discovery.

Mark earned his doctorate in human genetics at the University of Utah, has authored over 40 scientific publications and holds multiple patents. He has contributed seminal discoveries in the field of heritable cardiac arrhythmias and developed the Familion™ diagnostic test for long QT syndrome. His primary interests are discovery of novel therapeutics, implementation of molecular diagnostics for personalized medicine and evolution of Digital Health Care and Integrated Patient Care Solutions to improve the lives of patients living with auto-immune disease.

Andrew Holman

Andrew Holman
Chief Executive Officer & Co-founder
Inmedix Inc and Inmedix UK Ltd
Andrew Holman
Chief Executive Officer & Co-founder
Inmedix Inc and Inmedix UK Ltd
 
About Speaker:

Andrew J. Holman, M.D., is a clinical rheumatologist, CEO and Co-founder of Inmedix, Inc. in Seattle and its subsidiary, Inmedix UK, Ltd. He established Inmedix to validate and commercialize autonomic nervous system (ANS) diagnostics and therapeutics to enhance immunosuppressive outcomes for patients with autoimmune diseases. He trained at the University of Washington (rheumatology fellowship), Presbyterian-St. Luke’s Medical Center (internal medicine residency), the University of Missouri-Columbia (M.D.) and Bowdoin College (A.B., Chemistry). Currently, he is also a Clinical Associate Professor Medicine at the University of Washington. His research identified the role of ANS assessment as a predictor of immunosuppressive treatment outcomes in patients with autoimmune diseases as well as how to enhance those outcomes through adjunctive ANS therapeutics. He discovered the role of dopamine agonists in the treatment of fibromyalgia and elucidated the dysautonomic effects of positional cervical cord compression (PC3) in humans with widespread pain.

Toshiaki Kawakami

Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
 
About Speaker:

1978 MD, 1983 PhD from The University of Tokyo
1984-88 Postdoc at the NCI/NIH
1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI)
2000 Professor, LJI

Klaus Meyer Moller

Klaus Meyer Moller
Head of Business Development
Nordic Bioscience A/S
Klaus Meyer Moller
Head of Business Development
Nordic Bioscience A/S
 
About Speaker:
Calixte Monast

Calixte Monast
Senior Scientist
Janssen R&D
Calixte Monast
Senior Scientist
Janssen R&D
 
About Speaker:

Cal received his PhD from the University of Pennsylvania where he worked on computational and experimental analysis of signal transduction. For the last five years, Cal has worked as a computational biologist in the Immunology Biomarker department at Janssen R&D with a focus on inflammatory bowel disease. Cal's projects include identifying surrogate markers for disease severity, developing strategies for patient stratification, and executing biomarker strategies in early phase clinical studies.

Eric Sasso

Eric Sasso
Vice President, Medical & Scientific Affairs
Crescendo Bioscience
Eric Sasso
Vice President, Medical & Scientific Affairs
Crescendo Bioscience
 
About Speaker:

Dr. Sasso joined Crescendo Bioscience in 2012, where he has helped lead the Vectra medical development program to gain Medicare coverage, launch the pivotal clinical outcomes study and expand the validity and utility of Vectra DA as a predictor of radiographic progression. Dr. Sasso came to Crescendo from Abbott Laboratories, where he worked in Early Immunology Clinical Development and Humira Medical Affairs. Prior to joining Abbott in 2004, he was at the University of Washington, Seattle, where he is currently an Affiliate Professor of Medicine. Dr. Sasso earned an A.B. Biochemistry degree at Harvard University, Cambridge, MA, an M.D. degree from the University of California, San Diego and has trained in internal medicine at McGill University, Montreal, rheumatology at the University of Washington, and immunology at the Virginia Mason Research Center, Seattle. He has published extensively in the fields of rheumatology, immunology and dermatology.

Anuraag Shrivastav

Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
 
About Speaker:

Dr. Anuraag Shrivastav completed his PhD in 2002 from the Banaras Hindu University, India. He received postdoctoral fellowship from Canadian Institutes of Health Research and obtained postdoctoral training at the department of Pathology and Laboratory Medicine and Saskatchewan Cancer Agency, University of Saskatchewan, Canada. Dr Shrivastav is a faculty member at the University of Winnipeg and adjunct member at the University of Manitoba and CancerCare Manitoba. He has published over 40 peer-reviewed articles in International journals of repute. His laboratory is engaged in studying cellular signaling mechanisms that are intricately linked to homeostasis that control cell proliferation, survival and death in cancer cells. Currently, his research group is actively pursuing scientific research to identify novel markers for CRC screening and early detection. Dr. Shrivastav is also Principal, VastCon Inc – A University of Winnipeg spinoff dedicated to developing novel biomarkers based simple prognostic/diagnostic tests.

Xuemei Zhao

Xuemei Zhao
Senior Principal Scientist
Merck
Xuemei Zhao
Senior Principal Scientist
Merck
 
About Speaker:

Xuemei Zhao obtained her Ph.D. in Chemistry at Columbia University and did her postdoctoral training at Cold Spring Harbor Laboratory.  Afterwards, Xuemei joined the Proteomics Department at Merck Research Laboratories.  Her group was responsible for biochemical sample preparation for LC-MS based proteomics profiling in biomarker discovery and new target identification.  Xuemei then moved on to focus on clinical biomarker development and implementation.  Currently, Xuemei leads the immunoassay group in Translational Molecular Biomarkers to support clinical programs across all disease areas at Merck.

Neurological Biomarkers
DISTINGUISHED SPEAKERS
Richard Batrla-Utermann

Richard Batrla-Utermann
Medical Director
Roche
Richard Batrla-Utermann
Medical Director
Roche
 
About Speaker:

Global Clinical Director, Personalized Healthcare and Neurology, Roche Professional Diagnostics, Medical and Scientific Affairs, Roche Diagnostics International AG, Rotkreuz

International Medical Director, Pharma Business/Global Product Strategy, Medical Affairs/Medical Marketing, F. Hoffmann-La Roche Ltd.

Global Alliance Director, Pharma Partnering, F. Hoffmann-La Roche Ltd.

Head of Scientific Business Development, mtm laboratories AG, Heidelberg

Mark Frasier

Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
 
About Speaker:

Dr. Frasier has been with the Michael J Fox Foundation since 2006. He earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease.

Arti Gaur

Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
 
About Speaker:

Dr. Gaur is an Assistant Professor of Neurology and Member of the Norris Cotton Cancer Center at the Geisel School of Medicine, Dartmouth. She received her BS from Rochester Institute of Technology, NY; an MS from University of Rochester, NY and her PhD from University of Cologne, Germany.

At Dartmouth, her group studies the molecular basis of neurological pathologies, specifically gliomas. Dr. Gaur is the Study Chair on an Alliance funded, multi-institutional, prospective clinical trial that is establishing a comprehensive panel of diagnostic and prognostic markers as well as biomarkers of tumor burden, treatment efficacy and toxicity. Furthermore in this trial her group is testing patient tumors ex vivo and establishing novel therapies to treat gliomas.  The other sites for this trial are University of Vermont Medical Center, Tufts Medical Center and Massachussets General Hospital.  Additionally, Dr. Gaur’s group is also developing innovative, in vivo wireless, nano scale devices, to measure multiple biomarkers of health that can predict and track the course of diseases, enable real-time evaluation of treatment efficacy and deliver targeted therapies in patients suffering from incurable and debilitating neurological disorders.

Andreas Jeromin

Andreas Jeromin
Scientific and Medical Advisor
Quanterix
Andreas Jeromin
Scientific and Medical Advisor
Quanterix
 
About Speaker:

Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Officer to Quanterix Corp.

Christian Loch

Christian Loch
Chief Executive & Science Officer
AVMBioMed
Christian Loch
Chief Executive & Science Officer
AVMBioMed
 
About Speaker:

Christian Loch is Chief Executive and Science Officer of AVMBioMed; and adjunct faculty in the Department of Chemistry at Villanova University where he teaches proteomics in the graduate school.  AVMBioMed is a full service proteomic CRO serving academics and industry alike. Our signature epi-proteomic assay called Snapshot ProteomicsTM utilizes protein microarrays to extract information about 23,000 proteins per run with >95% reproducibility from complex samples like cell lysates and human serum. Prior to AVMBioMed, Christian directed R&D at a small biotechnology company where he led teams in development of assays and reagents useful to the study of the ubiquitin proteasomal pathway.  His interest in post-translational modification began during PhD studies at the University of Virginia, where he studied epigenetics and chromosomal remodeling in yeast.  His postdoctoral studies at the Fred Hutchinson Cancer Research Center in Seattle involved using mass spectrometry and antibody microarray technologies applied towards biomarker discovery.  To better appreciate and handle the challenges of performing proteomic studies in human populations, he also obtained a Master’s in Public Health-Epidemiology from the University of Washington during this time.  He is former Fellow of both the Canary Foundation and the American Cancer Society. 

Robert Rissman

Robert Rissman
Associate Professor
University of California, San Diego
Robert Rissman
Associate Professor
University of California, San Diego
 
About Speaker:

Dr. Rissman's work at UCSD is split into several parts that are balanced relatively equally. The goal of his basic science research is to discover novel biomarkers for neurodegenerative diseases with a specific focus on blood-based biomarkers. Of primary interest is the study of the biomarker utility and pathologic potential of neuronally-derived exosomes. Dr. Rissman's in vivo work is focused on the contribution of stress and changes in stress signaling intermediates in Alzheimer’s disease neuropathology and the discovery of compounds that impact the corticotropin-releasing factor system in Alzheimer's Disease.

In addition to the research program, Dr. Rissman is the Director for the Alzheimer's Disease Cooperative Study (ADCS) Biomarker Core and the Neuropathology/Brain Bank for the Alzheimer’s Disease Research Center (ADRC) at UCSD. Both cores are comprised by wet laboratories and a biospecimen banks.

Dr. Rissman is also the PI of UCSD’s Neuroplasticity of Aging Training Grant (T32) and teach graduate classes in the Neurobiology of Disease.

Douglas Scharre

Douglas Scharre
Director, Division of Cognitive Neurology, Department of Neurology
Ohio State University, Wexner Medical Centre
Douglas Scharre
Director, Division of Cognitive Neurology, Department of Neurology
Ohio State University, Wexner Medical Centre
 
About Speaker:

Dr. Douglas W. Scharre is the Director, Division of Cognitive Neurology and the Medical Director of The Ohio State University Center for Cognitive and Memory Disorders. He is a clinical researcher and behavioral neurologist specializing in the diagnosis and management of cognitive issues for over 20 years. He has conducted or participated in over 140 clinical research studies in dementia and mild cognitive impairment, funded by NIH, foundations and industry, utilizing neuroimaging (anatomical and functional (resting and task-activated) MRI, PET, and SPECT), serum and cerebrospinal fluid biomarkers, cognitive biomarkers, genetic biomarkers, and cognitive, functional, and behavioral scales on dementia and control subjects. He has designed and developed both paper and digital versions of the Self-Administered Gerocognitive Examination (SAGE), a cognitive assessment instrument designed for identifying individuals in a practical way with mild cognitive impairment or early dementia from any cause and to be sensitive to changes over time. He lectures frequently on topics of dementia, Alzheimer's disease, behavioral management of dementia and other aspects of cognitive neurology. Dr. Scharre joined The Ohio State University Wexner Medical Center faculty in the Department of Neurology in 1993. Dr. Scharre is board certified in neurology and in behavioral neurology and neuropsychiatry with special interests in cognitive assessment, degenerative dementias and dementia-related behaviors.